epocrates logo
epocrates logo
epocrates logo
  • 0

Drugs


Formulary
No Formulary Selected

Classes

  • All Drugs
  • Allergy/Cold/ENT
  • Anesthesia/Pain Management
  • Asthma/Pulmonary
  • Cardiovascular
  • Dental/Oral Care
  • Dermatologic
  • Diagnostic
  • Emergency
  • Endocrine/Metabolism
  • Gastrointestinal
  • Hematology/Oncology
  • Immunizations
  • Immunology
  • Infectious Disease
  • Nephrology/Urology
  • Neurologic
  • Nutrition/Electrolytes
  • Obstetrics/Gynecology
  • Ophthalmic
  • Psychiatric
  • Rheumatologic

Drug Names

# A B C D E F G H  I  J K L M N O P Q R S T U V W X Y Z
A+D Anti-Chafing Ointment
A+D Diaper Rash Cream
A+D First Aid Ointment
A+D Incontinence Support Skin Protectant & Rash Ointment
A+D Medicated Rash Ointment
A+D Original Ointment
A+D Overnight Healing Rash Ointment
abacavir
abacavir/dolutegravir/lamivudine
abacavir/lamivudine
abacavir/lamivudine/zidovudine
abaloparatide
abametapir topical
abatacept
Abecma
Abelcet
abemaciclib
Abigale
Abigale Lo
Abilify
Abilify Asimtufii
Abilify Discmelt
Abilify Maintena
Abilify MyCite
abiraterone acetate
abiraterone acetate micronized
Ablysinol
abobotulinumtoxinA
Abraxane
Abreva
Abreva Rapid Pain Relief
Abrilada (adalimumab-afzb)
abrocitinib
Abrysvo
Absorica
Absorica LD
Abstral
acalabrutinib
ACAM2000
acamprosate
Acanya
acarbose
Accolate
Accrufer
AccuNeb
Accupril
Accuretic
Accutane
acebutolol
aceclidine ophthalmic
Aceon
Acetadote
acetaminophen
acetaminophen rectal
acetaminophen/aspirin
acetaminophen/aspirin/caffeine
acetaminophen/aspirin/diphenhydramine
acetaminophen/caffeine
acetaminophen/caffeine/dihydrocodeine
acetaminophen/caffeine/pyrilamine
acetaminophen/chlorpheniramine
acetaminophen/chlorpheniramine/dextromethorphan
acetaminophen/chlorpheniramine/dextromethorphan/phenylephrine
acetaminophen/chlorpheniramine/dextromethorphan/pseudoephedrine
acetaminophen/chlorpheniramine/phenylephrine
acetaminophen/codeine
acetaminophen/dextromethorphan
acetaminophen/dextromethorphan/guaifenesin
acetaminophen/dextromethorphan/phenylephrine
acetaminophen/dextromethorphan/phenylephrine/guaifenesin
acetaminophen/dextromethorphan/pseudoephedrine
acetaminophen/diphenhydramine
acetaminophen/diphenhydramine/phenylephrine
acetaminophen/doxylamine/dextromethorphan
acetaminophen/doxylamine/dextromethorphan/phenylephrine
acetaminophen/guaifenesin
acetaminophen/ibuprofen
acetaminophen/pamabrom
acetaminophen/pamabrom/pyrilamine
acetaminophen/phenylephrine
acetaminophen/phenylephrine/guaifenesin
acetaminophen/pseudoephedrine
acetaminophen/triprolidine/dextromethorphan
acetaminophen/triprolidine/dextromethorphan/phenylephrine
acetazolamide
acetic acid otic
acetohydroxamic acid
acetylcholine intraocular
acetylcysteine
Aciphex
Aciphex Sprinkle
acitretin
aclidinium bromide inhaled
aclidinium bromide/formoterol inhaled
Aclovate
acoltremon ophthalmic
acoramidis
acrivastine/pseudoephedrine
Actemra
Acthar Gel
ActHIB
Acticlate
Actidose with Sorbitol
Actidose-Aqua
Actigall
Actimmune
Actiq
Activase
Activella
Actonel
Actonel with Calcium
ACTOplus met
ACTOplus met XR
Actos
Acular
Acular LS
Acuvail
Acuvue Theravision with Ketotifen
acyclovir
acyclovir oropharyngeal
acyclovir topical
acyclovir/hydrocortisone topical
Aczone
Adacel
adagrasib
Adakveo (crizanlizumab-tmca)
Adalat CC
adalimumab
ADAMTS13, recombinant
adapalene topical
adapalene/benzoyl peroxide topical
Adasuve
Adbry (tralokinumab-ldrm)
Adcetris
Adcirca
Adderall
Adderall XR
Addyi
adefovir dipivoxil
Adempas
Adenocard
Adenoscan
adenosine
adenovirus type 4 and type 7 vaccine, live oral
Adhansia XR
Adipex-P
Adlarity
Adlyxin
Admelog
ado-trastuzumab emtansine
Adoxa
Adquey
Adrenaclick
Adrenalin
Adriamycin
Adrucil
Adstiladrin (nadofaragene firadenovec-vncg)
aducanumab
Aduhelm (aducanumab-avwa)
Advair Diskus
Advair HFA
Advate
Advil
Advil Allergy & Congestion Relief
Advil Allergy Sinus
Advil Cold & Sinus
Advil Dual Action with Acetaminophen
Advil Dual Action with Acetaminophen Back Pain
Advil Migraine
Advil Multi-Symptom Cold & Flu
Advil PM
Advil Sinus Congestion & Pain
Advil Targeted Relief Cream
Adynovate
Adzenys ER
Adzenys XR-ODT
Adzynma (ADAMTS13, recombinant-krhn)
Aemcolo
afamelanotide
afamitresgene autoleucel
afatinib
Afeditab CR
aficamten
Afinitor
Afinitor Disperz
aflibercept intravitreal
Afluria
Afrezza
Afrin Allergy Sinus
Afrin No Drip Allergy Sinus
Afrin No Drip Allergy Sinus Night
Afrin No Drip Extra Moisturizing
Afrin No Drip Night
Afrin No Drip Original
Afrin No Drip Severe Congestion
Afrin Original
Afrin Severe Congestion
Afstyla
agalsidase beta
Agamree
Aggrastat
Aggrenox
Agrylin
Ahzantive (aflibercept-mrbb)
Aimovig (erenumab-aooe)
air polymer-type A
AirDuo Digihaler
AirDuo RespiClick
Airsupra
Ajovy (fremanezumab-vfrm)
AK-Dilate
AK-Poly-Bac
Akeega
Aklief
Akne-mycin
Akovaz
Akten
Aktipak
Akynzeo
Akynzeo IV
Ala-hist IR
Alahist CF
Alahist D
Alahist DM
Alahist PE
Alamast
Alavert
Alavert D-12 Hour
Alaway
albendazole
Albenza
albiglutide
Albuked
albumin (human)
Albuminar
Albuminex (albumin (human)-kjda)
AlbuRx
Albutein
albuterol
albuterol inhaled
albuterol/budesonide inhaled
alcaftadine ophthalmic
Alcaine
alclometasone topical
Aldactazide
Aldactone
Aldara
aldesleukin
Aldomet
Aldurazyme
Alecensa
alectinib
alemtuzumab
alendronate
alendronate/cholecalciferol
Alesse
Aleve
Aleve Arthritis Pain Gel
Aleve Back & Muscle Pain
Aleve Headache Pain
Aleve PM
Aleve-D Sinus & Cold
AleveX Lotion
AleveX Spray
Alfenta
alfentanil
alfuzosin
alglucosidase alfa
Alhemo (concizumab-mtci)
Alimta
Alinia
Aliqopa
alirocumab
aliskiren
aliskiren/hydrochlorothiazide
alitretinoin topical
Alka-Seltzer Cool Action Heartburn Relief Gum
Alka-Seltzer Extra Strength Heartburn ReliefChews
Alka-Seltzer Extra Strength Upset Stomach Relief
Alka-Seltzer Hangover Relief
Alka-Seltzer Heartburn + Gas ReliefChews
Alka-Seltzer Original
Alka-Seltzer Plus Cold & Flu FizzyChews
Alka-Seltzer Plus Cough & Sore Throat FizzyChews
Alka-Seltzer Plus Maximum Strength Cold & Cough
Alka-Seltzer Plus Maximum Strength Cold & Cough PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Day
Alka-Seltzer Plus Maximum Strength Cold & Flu Day PowerMax
Alka-Seltzer Plus Maximum Strength Cold & Flu Night
Alka-Seltzer Plus Maximum Strength Cold & Flu Night PowerMax
Alka-Seltzer Plus Maximum Strength Cough & Chest Congestion Power...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Cough, Mucus & Congestion Powe...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerF...
Alka-Seltzer Plus Maximum Strength Sinus Congestion & Pain PowerM...
Alka-Seltzer Plus Maximum Strength Sinus, Allergy & Cough PowerMa...
Alka-Seltzer Plus Severe Cold & Cough PowerFast Fizz
Alka-Seltzer Plus Severe Cold & Flu Day
Alka-Seltzer Plus Severe Cold & Flu Night
Alka-Seltzer Plus Severe Cold & Flu PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz
Alka-Seltzer Plus Severe Cold PowerFast Fizz Night
Alka-Seltzer Plus Severe Cold PowerFast Fizz Non-Drowsy
Alka-Seltzer Plus Severe Sinus, Cold & Cough
Alka-Seltzer Upset Stomach Relief
Alkeran
Alkindi Sprinkle
Allegra Allergy 12 Hour
Allegra Allergy 24 Hour
Allegra Hives 24 Hour
Allegra-D 12 Hour Allergy & Congestion
Allegra-D 24 Hour Allergy & Congestion
Aller-chlor
Alli
allogeneic cell therapy
allopurinol
Allzital
almotriptan
Alocril
alogliptin
alogliptin/metformin
alogliptin/pioglitazone
Alomide
Aloprim
Alora
alosetron
Aloxi
alpelisib
alpha-tocopherol (vitamin E)
alpha1-proteinase inhibitor
Alphagan P
Alphanate
alprazolam
Alprolix
alprostadil
alprostadil intracavernous
alprostadil intraurethral
Alrex
Alsuma
Altabax
Altace
Altafluor Benox
Altavera
alteplase
alteplase intracatheter
Altoprev
Altreno
Altuviiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusio...
aluminum acetate topical (modified Burow's solution)
aluminum chloride topical
aluminum hydroxide
aluminum hydroxide/magnesium carbonate
aluminum hydroxide/magnesium hydroxide
aluminum hydroxide/magnesium hydroxide/simethicone
Alunbrig
Alvaiz
Alvesco
alvimopan
Alyacen 1/35
Alyacen 7/7/7
Alyftrek
Alyglo (immune globulin human-stwk)
Alymsys (bevacizumab-maly)
Alyq
Amabelz
amantadine
Amaryl
Ambien
Ambien CR
AmBisome
ambrisentan
amcinonide topical
Ameluz
Amerge
Amethia
Amethia Lo
Amethyst
Amicar
Amidate
amifampridine
amifostine
amikacin
amikacin liposomal inhaled
Amikin
amiloride
amiloride/hydrochlorothiazide
aminocaproic acid
aminolevulinic acid topical
aminophylline
amiodarone
amisulpride
Amitiza
amitriptyline
amivantamab
amivantamab/hyaluronidase
Amjevita (adalimumab-atto)
amlodipine
amlodipine/atorvastatin
amlodipine/benazepril
amlodipine/celecoxib
amlodipine/olmesartan medoxomil
amlodipine/valsartan
amlodipine/valsartan/hydrochlorothiazide
ammonium lactate topical
Ammonul
Amnesteem
Amondys 45
amoxapine
amoxicillin
amoxicillin/clavulanate
Amoxil
Amphadase
amphetamine
Amphocin
Amphojel
Amphotec
amphotericin B cholesteryl sulfate
amphotericin B deoxycholate
amphotericin B lipid complex
amphotericin B liposomal
ampicillin
ampicillin/sulbactam
Ampyra
Amrix
Amtagvi
Amvuttra
amyl nitrite/sodium nitrite/sodium thiosulfate
Amzeeq
anacaulase topical
Anacin
Anafranil
anagrelide
anakinra
Analpram E
Analpram HC
AnaMantle HC
Anaphylm
Anaprox
Anaprox DS
Anascorp
Anaspaz
anastrozole
Anavip
Anbesol Maximum Strength
Ancef
Ancobon
Andembry (garadacimab-gxii)
Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)
Androderm
AndroGel
Android
Androxy
Anectine
Angeliq
Angiomax
Angiomax RTU
angiotensin II
anidulafungin
anifrolumab
Anjeso
Anktiva (nogapendekin alfa inbakicept-pmln)
Annovera
Anoro Ellipta
Ansaid
ansuvimab
Antabuse
Antara
Anthim
Anthrasil
anthrax immune globulin (human)
anthrax vaccine
anthrax vaccine, adjuvanted
anti-inhibitor coagulant complex
anti-thymocyte globulin (rabbit)
antihemophilic factor (factor VIII, human)
antihemophilic factor (factor VIII, human)/von Willebrand factor ...
antihemophilic factor (factor VIII, recombinant)
antihemophilic factor (factor VIII, recombinant), Fc fusion prote...
antihemophilic factor (factor VIII, recombinant), glycopegylated
antihemophilic factor (factor VIII, recombinant), pegylated
antihemophilic factor (factor VIII, recombinant), porcine
antihemophilic factor (factor VIII, recombinant), single chain
antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein
antipyrine/benzocaine otic
antithrombin (recombinant)
antithrombin III
Antivert
Antizol
Anucort-HC
Anusol-HC Cream
Anusol-HC Suppository
Anzupgo
Apadaz
apalutamide
ApexiCon
ApexiCon E
Aphexda
Apidra
apitegromab
Apitegromab
apixaban
Aplenzin
Aplisol
Apokyn
apomorphine
Aponvie
apraclonidine ophthalmic
apremilast
aprepitant
Apresoline
Apretude
Apri
Apriso
aprocitentan
Aptensio XR
Aptiom
Aptivus
Aqneursa
Aquaphor
Aquaphor Baby Diaper Rash
Aquaphor Itch Relief
Aquasol A
Aquasol E
Aqvesme
Arakoda
Aralast NP
Aralen
Aranelle
Aranesp
Arava
Arazlo
Arbinoxa
Arbli
Arcalyst
Aredia
Arepanrix
Arexvy
arformoterol inhaled
argatroban
arginine
Aricept
Aricept ODT
Arikayce
Arimidex
arimoclomol
aripiprazole
aripiprazole bimonthly injection
aripiprazole lauroxil
aripiprazole monthly injection
Aristada
Aristada Initio
Arixtra
Armlupeg (pegfilgrastim-unne)
armodafinil
ArmonAir Digihaler
ArmonAir RespiClick
Armour Thyroid
Arnuity Ellipta
Aromasin
Arranon
arsenic trioxide
Artane
artemether/lumefantrine
artesunate
Arthriten
Arthritis Hot
Arthrotec
articaine/epinephrine
Arymo ER
Arynta
Arzerra
Asacol
Asacol HD
Asceniv (immune globulin human-slra)
asciminib
Ascor
ascorbic acid (vitamin C)
asenapine
asenapine transdermal
asfotase alfa
Ashlyna
Asmanex HFA
Asmanex Twisthaler
asparaginase
asparaginase Erwinia chrysanthemi
asparaginase erwinia chrysanthemi (recombinant)
Asparlas (calaspargase pegol-mknl)
Aspercreme
Aspercreme Arthritis Pain
Aspercreme Lidocaine 3 in 1 Foot Pain Relief Cream
Aspercreme Lidocaine Foot Pain Cream for Diabetic Skin
Aspercreme Lidocaine Pain Relief Cream
Aspercreme Lidocaine Pain Relief Liquid Roll-On
Aspercreme Lidocaine Pain Relief Patch
Aspercreme Lidocaine Pain Relief Spray
aspirin
aspirin/caffeine
aspirin/chlorpheniramine/dextromethorphan/phenylephrine
aspirin/chlorpheniramine/phenylephrine
aspirin/dextromethorphan/phenylephrine
aspirin/dipyridamole
aspirin/omeprazole
Aspruzyo Sprinkle
Astagraf XL
Astelin
Astepro Allergy
Asthmanefrin
Atacand
Atacand HCT
atacicept
Atacicept
Atarax
atazanavir
atazanavir/cobicistat
Atelvia
atenolol
atenolol/chlorthalidone
atezolizumab
atezolizumab/hyaluronidase
Atgam
atidarsagene autotemcel
Ativan
Atmeksi
atogepant
atoltivimab/maftivimab/odesivimab
atomoxetine
Atoncy
Atorvaliq
atorvastatin
atovaquone
atovaquone/proguanil
atracurium
Atralin
atrasentan
Atripla
AtroPen
atropine
atropine ophthalmic
atropine/pralidoxime
Atrovent HFA
Atrovent Nasal
ATryn
Attruby
Atzumi
Aubagio
Aubra EQ
Aucatzyl
Audenz
Augmentin
Augmentin ES-600
Augmentin XR
Augtyro
Aukelso (denosumab-kyqq)
Auralgan (original formulation)
auranofin
Aurlumyn
Aurovela 1.5/30
Aurovela 1/20
Aurovela 24 Fe
Aurovela Fe 1.5/30
Aurovela Fe 1/20
Auryxia
Austedo
Austedo XR
autologous mesenchymal stem cell-neurotrophic factor (MSC-NTF) ce...
Auvelity
Auvi-Q
avacincaptad pegol intravitreal
avacopan
Avage
avalglucosidase alfa
Avalide
avanafil
Avandaryl
Avandia
avapritinib
Avapro
avasopasem
Avasopasem
Avastin
avatrombopag
Aveed
Aveeno Anti-Itch Concentrated Lotion
Aveeno Baby Calming Comfort Lotion
Aveeno Baby Daily Moisture Cream
Aveeno Baby Daily Moisture Lotion
Aveeno Baby Eczema Therapy Moisturizing Cream
Aveeno Baby Eczema Therapy Nighttime Balm
Aveeno Baby Eczema Therapy Soothing Bath Treatment
Aveeno Calm + Restore Skin Therapy Balm
Aveeno Daily Moisturizing Lotion
Aveeno Eczema Therapy Moisturizing Cream
Aveeno Eczema Therapy Nighttime Itch Relief Balm
Aveeno Eczema Therapy Rescue Relief Treatment Gel Cream
Aveeno Hydrocortisone Anti-Itch Cream
Aveeno Positively Radiant Clear Complexion
Aveeno Skin Relief Hand Cream
Aveeno Skin Relief Moisturizing Lotion
Aveeno Skin Relief Overnight Cream
Aveeno Soothing Bath Treatment
Avelox
avelumab
Averi
Avgemsi
Aviane
Avidoxy
Avinza
Avita
Avlayah (tividenofusp alfa-eknm)
Avmapki Fakzynja Co-Pack
Avodart
Avonex
Avopef
Avsola (infliximab-axxq)
Avtozma (tocilizumab-anoh)
avutometinib and defactinib
Avycaz
Avzivi (bevacizumab-tnjn)
Awiqli (insulin icodec-abae)
axatilimab
Axert
axicabtagene ciloleucel
Axid
Axiron
axitinib
Axtle
Aygestin
Ayvakit
azacitidine
Azactam
Azasan
AzaSite
azathioprine
Azedra
azelaic acid topical
azelastine nasal
azelastine ophthalmic
azelastine/fluticasone propionate nasal
Azelex
Azilect
azilsartan medoxomil
azilsartan medoxomil/chlorthalidone
azithromycin
azithromycin ophthalmic
Azmacort
Azmiro
Azo Urinary Pain Relief
Azo Urinary Pain Relief Maximum Strength
Azopt
Azor
Azstarys
aztreonam
aztreonam inhaled
aztreonam/avibactam
Azulfidine
Azulfidine EN-tabs
Azurette

close

 

Select a medication above to begin.

Trodelvy (sacituzumab govitecan-hziy)

sacituzumab govitecan

Drug Monograph

  • Black Box Warnings
  • Adult Dosing
  • Peds Dosing
  • Contraindications/Cautions
  • Drug Interactions
  • Adverse Reactions
  • Safety/Monitoring
  • Pregnancy/Lactation
  • Pharmacology
  • Formulary
  • Manufacturer/Pricing
  • Patient Education
  • Pill Pictures
  • Add to Interaction Check
  • Dosing Calculator

Black Box Warnings .

Neutropenia

severe, life-threatening, or fatal cases may occur; hold tx if ANC <1500/mm^3 on day 1 of cycle, ANC <1000/mm^3 on day 8 of cycle, or febrile neutropenia; monitor CBC with diff during tx; give primary prophylaxis with G-CSF starting 1st tx cycle in all patients with incr. febrile neutropenia risk; initiate antimicrobial tx immediately if febrile neutropenia

Diarrhea

severe cases may occur; hold tx for severe cases until resolved to Grade 1 or less, and reduce subsequent doses; monitor patients with diarrhea, give fluid and electrolytes as needed; at the onset of diarrhea, evaluate for infectious cases and if negative, promptly initiate loperamide

Adult Dosing .

Dosage forms:  INJ

Special Note

[equivalency or interchangeability info]
Info: not interchangeable with other irinotecan- or SN-38-containing products
[drug name clarification]
Info: nonproprietary name = sacituzumab govitecan-hziy
[uses, dosing may vary]
Info: refer to institution protocols and pkg insert prior to prescribing for uses, premeds, and dosing including toxicity-related dose adjustments

breast CA, unresectable locally advanced or metastatic

[ER/PR-negative HER2-negative disease]
Dose: 10 mg/kg/dose IV x1 on days 1, 8 of 21-day cycle; Max: 10 mg/kg/dose; Info: for patients who have received at least 2 systemic tx
[hormone receptor-positive HER2-negative disease]
Dose: 10 mg/kg/dose IV x1 on days 1, 8 of 21-day cycle; Max: 10 mg/kg/dose; Info: for patients who have received endocrine-based tx and at least 2 additional systemic tx

urothelial carcinoma, locally advanced or metastatic

[indication withdrawn in US]
Info: drug not shown to improve survival in patients with locally advanced or metastatic urothelial carcinoma who have received platinum-containing chemo and PD-1/PD-L1 inhibitor

renal dosing

[see below]
CrCl >30: no adjustment; CrCl <30: not defined
HD/PD: not defined

hepatic dosing

[see below]
bilirubin <1.5x ULN: no adjustment; bilirubin >1.5x ULN: not defined

Peds Dosing .

Peds dosing is currently unavailable or not applicable for this drug.

Contraindications / Cautions .

    com.epocrates.rxweb.beans.StringCollection@2f4ef885
  • hypersensitivity to drug or ingredient
  • ANC <1500 on day 1 of cycle
  • ANC <1000 on day 8 of cycle
  • avoid: breastfeeding during tx and x1mo after D/C
  • caution: patients of childbearing potential
  • caution: male patients of reproductive potential
  • caution: patients 65 yo and older
  • caution: UGT1A1*28 allele carriers

Drug Interactions .

Overview

sacituzumab govitecan

DNA topoisomerase I inhibitor

Interaction Characteristics:
  • UGT1A1 substrate
  • hypokalemia
  • hypophosphatemia
  • myelosuppressive oncologic agent
  • prolongs QT interval (conditional)

Contraindicated

  • pimozide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    pimozide
    1 interaction

    Contraindicated

    sacituzumab govitecan + pimozide

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • thioridazine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    thioridazine
    1 interaction

    Contraindicated

    sacituzumab govitecan + thioridazine

    contraindicated: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Avoid/Use Alternative

  • arsenic trioxide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    arsenic trioxide
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + arsenic trioxide

    use alternative or monitor ECG, potassium: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

  • atazanavir
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    atazanavir
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + atazanavir

    avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

  • bedaquiline
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    bedaquiline
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + bedaquiline

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • belumosudil
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    belumosudil
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + belumosudil

    avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

  • butalbital
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    butalbital
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + butalbital

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT metabolism induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • capivasertib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    capivasertib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + capivasertib

    avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

  • carbamazepine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    carbamazepine
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + carbamazepine

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • chloramphenicol
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    chloramphenicol
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + chloramphenicol

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cisapride
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    cisapride
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + cisapride

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • cladribine oral
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    cladribine oral
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + cladribine oral

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • crizotinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    crizotinib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + crizotinib

    use alternative or monitor ECG, electrolytes, incl. potassium: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

  • deferiprone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    deferiprone
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + deferiprone

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • domperidone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    domperidone
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + domperidone

    use alternative or monitor ECG, HR, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dronedarone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    dronedarone
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + dronedarone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • efavirenz
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    efavirenz
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + efavirenz

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • ephedra
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ephedra
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + ephedra

    avoid combo: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • erdafitinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    erdafitinib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + erdafitinib

    avoid combo until after dose titration period at 14-21 days post erdafitinib tx initiation: combo may interfere with erdafitinib dose titration (altered phosphate levels)

  • eribulin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    eribulin
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + eribulin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fexinidazole
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    fexinidazole
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + fexinidazole

    if possible, do not initiate fexinidazole until 5 half-lives after sacituzumab govitecan D/C; use alternative or monitor CBC, ECG during and x7 days after fexinidazole tx: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

  • fosfomycin injection
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    fosfomycin injection
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + fosfomycin injection

    use alternative or monitor ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression, hypokalemia (additive effects)

  • fosphenytoin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    fosphenytoin
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + fosphenytoin

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT metabolism induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • ganciclovir
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ganciclovir
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + ganciclovir

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • gemfibrozil
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    gemfibrozil
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + gemfibrozil

    avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

  • hydroxychloroquine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    hydroxychloroquine
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + hydroxychloroquine

    use alternative or monitor ECG, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

  • ketoconazole
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ketoconazole
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + ketoconazole

    avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

  • lefamulin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    lefamulin
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + lefamulin

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lenvatinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    lenvatinib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + lenvatinib

    avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT possibly inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

  • lonafarnib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    lonafarnib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + lonafarnib

    use alternative or monitor HR, ECG, electrolytes, CBC: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

  • lopinavir/ritonavir
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    lopinavir/ ritonavir
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + lopinavir/ ritonavir

    avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

  • lorlatinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    lorlatinib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + lorlatinib

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT metabolism induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • mitapivat
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    mitapivat
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + mitapivat

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT possibly induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • mobocertinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    mobocertinib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + mobocertinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • oxcarbazepine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    oxcarbazepine
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + oxcarbazepine

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • penicillamine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    penicillamine
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + penicillamine

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • pentamidine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    pentamidine
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + pentamidine

    use alternative or monitor ECG, CBC; risk may be lower w/ nebulized pentamidine: combo may incr. risk of QT prolongation, cardiac arrhythmias, myelosuppression (additive effects)

  • pentobarbital
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    pentobarbital
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + pentobarbital

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • pexidartinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    pexidartinib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + pexidartinib

    avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT possibly inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

  • phenobarbital
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    phenobarbital
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + phenobarbital

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • phenytoin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    phenytoin
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + phenytoin

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • primaquine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    primaquine
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + primaquine

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • primidone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    primidone
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + primidone

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • probenecid
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    probenecid
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + probenecid

    avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

  • quizartinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    quizartinib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + quizartinib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • radium Ra 223 dichloride
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    radium Ra 223 dichloride
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + radium Ra 223 dichloride

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • regorafenib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    regorafenib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + regorafenib

    avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

  • rifampin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    rifampin
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + rifampin

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • ritonavir
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ritonavir
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + ritonavir

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • ropeginterferon alfa-2b
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ropeginterferon alfa-2b
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + ropeginterferon alfa-2b

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sorafenib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sorafenib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + sorafenib

    avoid combo: combo may incr. SN-38 levels, risk of myelosuppression, other adverse effects (UGT inhibited, SN-38 active small molecule moiety of sacituzumab govitecan)

  • sotalol
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sotalol
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + sotalol

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • tipranavir
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    tipranavir
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + tipranavir

    avoid combo: combo may decr. SN-38 levels, efficacy (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan)

  • toremifene
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    toremifene
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + toremifene

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • valganciclovir
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    valganciclovir
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + valganciclovir

    use alternative or monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • valproic acid
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    valproic acid
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + valproic acid

    avoid combo: combo may decr. SN-38 levels, efficacy; may incr. risk of myelosuppression (UGT induced, SN-38 active small molecule moiety of sacituzumab govitecan; additive effects)

  • vandetanib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    vandetanib
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + vandetanib

    use alternative or monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ziprasidone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ziprasidone
    1 interaction

    Avoid/Use Alternative

    sacituzumab govitecan + ziprasidone

    use alternative or monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

Monitor/Modify Tx

  • abiraterone acetate
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    abiraterone acetate
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + abiraterone acetate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • acetazolamide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    acetazolamide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + acetazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • adagrasib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    adagrasib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + adagrasib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • albendazole
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    albendazole
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + albendazole

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • albuterol
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    albuterol
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + albuterol

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • albuterol inhaled
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    albuterol inhaled
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + albuterol inhaled

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • alemtuzumab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    alemtuzumab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + alemtuzumab

    monitor CBC; myelosuppression risk may be lower w/ alemtuzumab doses used for MS: combo may incr. risk of myelosuppression (additive effects)

  • allopurinol
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    allopurinol
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + allopurinol

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • aloe
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    aloe
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + aloe

    monitor potassium w/ aloe laxative doses: combo may incr. risk of hypokalemia (additive effects)

  • amiloride
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    amiloride
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + amiloride

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • amiodarone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    amiodarone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + amiodarone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • amphotericin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    amphotericin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + amphotericin

    monitor potassium, ECG: combo may incr. risk of hypokalemia, cardiac arrhythmias (additive effects)

  • anagrelide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    anagrelide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + anagrelide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • anti-thymocyte globulin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    anti-thymocyte globulin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + anti-thymocyte globulin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • apalutamide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    apalutamide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + apalutamide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • apomorphine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    apomorphine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + apomorphine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • arformoterol inhaled
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    arformoterol inhaled
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + arformoterol inhaled

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • artemether/lumefantrine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    artemether/ lumefantrine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + artemether/ lumefantrine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • asenapine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    asenapine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + asenapine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • asparaginase
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    asparaginase
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + asparaginase

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • atidarsagene autotemcel
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    atidarsagene autotemcel
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + atidarsagene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • auranofin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    auranofin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + auranofin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • azathioprine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    azathioprine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + azathioprine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • azithromycin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    azithromycin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + azithromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • balsalazide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    balsalazide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + balsalazide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • baricitinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    baricitinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + baricitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • benznidazole
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    benznidazole
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + benznidazole

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • betamethasone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    betamethasone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + betamethasone

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • betibeglogene autotemcel
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    betibeglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + betibeglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • brexucabtagene autoleucel
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    brexucabtagene autoleucel
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + brexucabtagene autoleucel

    monitor potassium, sodium, calcium: combo may incr. risk of hypokalemia, hyponatremia, hypocalcemia (additive effects)

  • budesonide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    budesonide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + budesonide

    monitor potassium: combo may incr. risk of hypokalemia (possible additive effects)

  • bumetanide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    bumetanide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + bumetanide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • cabozantinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    cabozantinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + cabozantinib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • carfilzomib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    carfilzomib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + carfilzomib

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • ceritinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ceritinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + ceritinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • cetuximab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    cetuximab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + cetuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • chloroquine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    chloroquine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + chloroquine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • chlorothiazide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    chlorothiazide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + chlorothiazide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • chlorpromazine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    chlorpromazine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + chlorpromazine

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • chlorthalidone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    chlorthalidone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + chlorthalidone

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • cidofovir
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    cidofovir
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + cidofovir

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • cisplatin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    cisplatin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + cisplatin

    monitor potassium, sodium, calcium: combo may incr. risk of hypokalemia, SIADH, hyponatremia, hypocalcemia (additive effects)

  • citalopram
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    citalopram
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + citalopram

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clarithromycin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    clarithromycin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + clarithromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clofazimine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    clofazimine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + clofazimine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • clomipramine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    clomipramine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + clomipramine

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • clozapine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    clozapine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + clozapine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • colchicine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    colchicine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + colchicine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • copper histidinate
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    copper histidinate
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + copper histidinate

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • corticotropin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    corticotropin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + corticotropin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • cortisone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    cortisone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + cortisone

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • cyclophosphamide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    cyclophosphamide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + cyclophosphamide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • dapsone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    dapsone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + dapsone

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • decitabine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    decitabine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + decitabine

    monitor potassium w/ IV decitabine use: combo may incr. risk of hypokalemia (additive effects)

  • deferasirox
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    deferasirox
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + deferasirox

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • deflazacort
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    deflazacort
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + deflazacort

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • degarelix
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    degarelix
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + degarelix

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • desflurane
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    desflurane
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + desflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • desipramine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    desipramine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + desipramine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • deuruxolitinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    deuruxolitinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + deuruxolitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • dexamethasone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    dexamethasone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + dexamethasone

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • dexmedetomidine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    dexmedetomidine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + dexmedetomidine

    monitor HR, ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexmedetomidine injection
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    dexmedetomidine injection
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + dexmedetomidine injection

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dexrazoxane
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    dexrazoxane
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + dexrazoxane

    monitor CBC if anthracycline extravasation or doxorubicin cardioprotective use, otherwise avoid combo: combo may incr. risk of myelosuppression; may decr. efficacy of cancer chemo (additive effects; mechanism unknown)

  • dichlorphenamide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    dichlorphenamide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + dichlorphenamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • dinutuximab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    dinutuximab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + dinutuximab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • disopyramide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    disopyramide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + disopyramide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dofetilide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    dofetilide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + dofetilide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • donepezil
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    donepezil
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + donepezil

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • dordaviprone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    dordaviprone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + dordaviprone

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • droperidol
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    droperidol
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + droperidol

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • efbemalenograstim alfa
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    efbemalenograstim alfa
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + efbemalenograstim alfa

    admin. efbemalenograstim at least 24h after or at least 14 days before myelosuppressive chemo: combo may decr. efbemalenograstim efficacy (antagonistic effects)

  • eflapegrastim (G-CSF)
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    eflapegrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + eflapegrastim (G-CSF)

    admin. eflapegrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. eflapegrastim efficacy (antagonistic effects)

  • elivaldogene autotemcel
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    elivaldogene autotemcel
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + elivaldogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression (additive effects)

  • emapalumab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    emapalumab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + emapalumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • encorafenib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    encorafenib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + encorafenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • epinephrine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    epinephrine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + epinephrine

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • epirubicin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    epirubicin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + epirubicin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • erythromycin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    erythromycin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + erythromycin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ethacrynic acid
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ethacrynic acid
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + ethacrynic acid

    monitor potassium, sodium, calcium: combo may incr. risk of hypokalemia, SIADH, hyponatremia, hypocalcemia (additive effects)

  • etuvetidigene autotemcel
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    etuvetidigene autotemcel
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + etuvetidigene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • everolimus
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    everolimus
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + everolimus

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • exagamglogene autotemcel
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    exagamglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + exagamglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • filgrastim (G-CSF)
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    filgrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + filgrastim (G-CSF)

    admin. filgrastim at least 24h before or after myelosuppressive chemo: combo may decr. filgrastim efficacy (antagonistic effects)

  • flecainide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    flecainide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + flecainide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • flucytosine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    flucytosine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + flucytosine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • fludrocortisone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    fludrocortisone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + fludrocortisone

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • fluorouracil
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    fluorouracil
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + fluorouracil

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • fluphenazine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    fluphenazine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + fluphenazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • formoterol inhaled
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    formoterol inhaled
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + formoterol inhaled

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • foscarnet
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    foscarnet
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + foscarnet

    monitor CBC, potassium, ECG: combo may incr. risk of myelosuppression, hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • fostamatinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    fostamatinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + fostamatinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • furosemide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    furosemide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + furosemide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • gentamicin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    gentamicin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + gentamicin

    monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

  • gilteritinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    gilteritinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + gilteritinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • givinostat
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    givinostat
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + givinostat

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • glasdegib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    glasdegib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + glasdegib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • goserelin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    goserelin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + goserelin

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • haloperidol
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    haloperidol
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + haloperidol

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • histrelin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    histrelin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + histrelin

    consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • hydrochlorothiazide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    hydrochlorothiazide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + hydrochlorothiazide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • hydrocortisone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    hydrocortisone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + hydrocortisone

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • hydroxyurea
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    hydroxyurea
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + hydroxyurea

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • hydroxyzine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    hydroxyzine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + hydroxyzine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ibutilide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ibutilide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + ibutilide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • imipramine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    imipramine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + imipramine

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • indapamide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    indapamide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + indapamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • inotuzumab ozogamicin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    inotuzumab ozogamicin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + inotuzumab ozogamicin

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • insulin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    insulin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + insulin

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • interferon beta 1a
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    interferon beta 1a
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + interferon beta 1a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • interferon beta 1b
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    interferon beta 1b
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + interferon beta 1b

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • interferon gamma 1b
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    interferon gamma 1b
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + interferon gamma 1b

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • isoflurane
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    isoflurane
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + isoflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • isoproterenol
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    isoproterenol
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + isoproterenol

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • ivosidenib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ivosidenib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + ivosidenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • leflunomide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    leflunomide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + leflunomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lenalidomide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    lenalidomide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + lenalidomide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • leuprolide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    leuprolide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + leuprolide

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • levalbuterol inhaled
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    levalbuterol inhaled
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + levalbuterol inhaled

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • levofloxacin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    levofloxacin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + levofloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • levoketoconazole
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    levoketoconazole
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + levoketoconazole

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • licorice
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    licorice
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + licorice

    monitor potassium w/ large amounts of licorice: combo may incr. risk of hypokalemia (additive effects)

  • linezolid
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    linezolid
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + linezolid

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • lofexidine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    lofexidine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + lofexidine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • lovotibeglogene autotemcel
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    lovotibeglogene autotemcel
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + lovotibeglogene autotemcel

    monitor CBC, bleeding s/sx: combo may incr. risk of myelosuppression, bleeding (additive effects)

  • lymphocyte immune globulin, anti-thymocyte globulin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    lymphocyte immune globulin, anti-thymocyte globulin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + lymphocyte immune globulin, anti-thymocyte globulin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • macimorelin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    macimorelin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + macimorelin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • magnesium citrate
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    magnesium citrate
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + magnesium citrate

    monitor potassium, consider monitoring ECG if magnesium citrate bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • mannitol
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    mannitol
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + mannitol

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • mercaptopurine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    mercaptopurine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + mercaptopurine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mesalamine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    mesalamine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + mesalamine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mesalamine rectal
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    mesalamine rectal
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + mesalamine rectal

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • methadone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    methadone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + methadone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • methazolamide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    methazolamide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + methazolamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • methotrexate
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    methotrexate
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + methotrexate

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • methylprednisolone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    methylprednisolone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + methylprednisolone

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • metolazone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    metolazone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + metolazone

    monitor potassium, sodium: combo may incr. risk of hypokalemia, SIADH, hyponatremia (additive effects)

  • mifepristone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    mifepristone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + mifepristone

    monitor potassium if daily mifepristone use: combo may incr. risk of hypokalemia (additive effects)

  • motixafortide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    motixafortide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + motixafortide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • moxifloxacin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    moxifloxacin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + moxifloxacin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • mycophenolate mofetil
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    mycophenolate mofetil
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + mycophenolate mofetil

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • mycophenolic acid
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    mycophenolic acid
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + mycophenolic acid

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • necitumumab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    necitumumab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + necitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • neomycin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    neomycin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + neomycin

    monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

  • nilotinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    nilotinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + nilotinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias, hypokalemia (additive effects)

  • oliceridine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    oliceridine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + oliceridine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • olodaterol inhaled
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    olodaterol inhaled
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + olodaterol inhaled

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • olsalazine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    olsalazine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + olsalazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ondansetron
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ondansetron
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + ondansetron

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • osilodrostat
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    osilodrostat
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + osilodrostat

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • osimertinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    osimertinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + osimertinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pacritinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    pacritinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + pacritinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • paliperidone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    paliperidone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + paliperidone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • palonosetron
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    palonosetron
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + palonosetron

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pamidronate
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    pamidronate
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + pamidronate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • panitumumab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    panitumumab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + panitumumab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • paromomycin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    paromomycin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + paromomycin

    monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

  • pasireotide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    pasireotide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + pasireotide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • pegfilgrastim (G-CSF)
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    pegfilgrastim (G-CSF)
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + pegfilgrastim (G-CSF)

    admin. pegfilgrastim >24h after or >14 days before myelosuppressive chemo: combo may decr. pegfilgrastim efficacy (antagonistic effects)

  • peginterferon alfa 2a
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    peginterferon alfa 2a
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + peginterferon alfa 2a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • peginterferon beta 1a
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    peginterferon beta 1a
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + peginterferon beta 1a

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • perphenazine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    perphenazine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + perphenazine

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • polyethylene glycol
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    polyethylene glycol
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + polyethylene glycol

    monitor potassium, consider monitoring ECG if polyethylene glycol bowel prep use: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • polyethylene glycol/electrolytes
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    polyethylene glycol/ electrolytes
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + polyethylene glycol/ electrolytes

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • posaconazole
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    posaconazole
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + posaconazole

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • prednisolone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    prednisolone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + prednisolone

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • prednisone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    prednisone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + prednisone

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • procainamide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    procainamide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + procainamide

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • proguanil
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    proguanil
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + proguanil

    monitor CBC, especially if concomitant renal impairment: combo may incr. risk of myelosuppression (additive effects)

  • propafenone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    propafenone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + propafenone

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • protriptyline
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    protriptyline
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + protriptyline

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • pyrimethamine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    pyrimethamine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + pyrimethamine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • quinidine (antiarrhythmic)
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    quinidine (antiarrhythmic)
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + quinidine (antiarrhythmic)

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quinidine (CYP2D6 inhibitor)
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    quinidine (CYP2D6 inhibitor)
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + quinidine (CYP2D6 inhibitor)

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • quinine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    quinine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + quinine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • revumenib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    revumenib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + revumenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ribavirin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ribavirin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + ribavirin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ribociclib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ribociclib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + ribociclib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • rifabutin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    rifabutin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + rifabutin

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • rituximab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    rituximab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + rituximab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • romidepsin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    romidepsin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + romidepsin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • rucaparib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    rucaparib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + rucaparib

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • ruxolitinib topical
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ruxolitinib topical
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + ruxolitinib topical

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • salmeterol inhaled
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    salmeterol inhaled
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + salmeterol inhaled

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sargramostim (GM-CSF)
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sargramostim (GM-CSF)
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sargramostim (GM-CSF)

    admin. sargramostim >24h before or after myelosuppressive chemo: combo may decr. sargramostim efficacy (antagonistic effects)

  • sarilumab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sarilumab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sarilumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • satralizumab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    satralizumab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + satralizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • selinexor
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    selinexor
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + selinexor

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • selpercatinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    selpercatinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + selpercatinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sevoflurane
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sevoflurane
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sevoflurane

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • sirolimus
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sirolimus
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sirolimus

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sirolimus albumin-bound
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sirolimus albumin-bound
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sirolimus albumin-bound

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium benzoate
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sodium benzoate
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sodium benzoate

    monitor potassium, especially if hyperammonemia use: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylacetate
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sodium phenylacetate
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sodium phenylacetate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium phenylbutyrate
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sodium phenylbutyrate
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sodium phenylbutyrate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • sodium polystyrene sulfonate
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sodium polystyrene sulfonate
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sodium polystyrene sulfonate

    monitor potassium, ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • sodium thiosulfate
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sodium thiosulfate
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sodium thiosulfate

    if ototoxicity risk reduction use, monitor potassium; otherwise, caution advised: combo may incr. risk of hypokalemia (additive effects)

  • stiripentol
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    stiripentol
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + stiripentol

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • streptomycin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    streptomycin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + streptomycin

    monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

  • succimer
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    succimer
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + succimer

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sulfasalazine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sulfasalazine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sulfasalazine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • sulfate bowel prep
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    sulfate bowel prep
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + sulfate bowel prep

    monitor potassium, consider monitoring ECG: combo may incr. risk of hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

  • tafasitamab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    tafasitamab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + tafasitamab

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • tagraxofusp
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    tagraxofusp
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + tagraxofusp

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • taletrectinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    taletrectinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + taletrectinib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • telavancin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    telavancin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + telavancin

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • teplizumab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    teplizumab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + teplizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • terbutaline
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    terbutaline
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + terbutaline

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • teriflunomide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    teriflunomide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + teriflunomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tetrabenazine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    tetrabenazine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + tetrabenazine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • thalidomide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    thalidomide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + thalidomide

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tobramycin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    tobramycin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + tobramycin

    monitor calcium: combo may incr. risk of hypocalcemia (additive effects)

  • tocilizumab
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    tocilizumab
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + tocilizumab

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • tofacitinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    tofacitinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + tofacitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • topiramate
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    topiramate
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + topiramate

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • torsemide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    torsemide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + torsemide

    monitor potassium, sodium, calcium: combo may incr. risk of hypokalemia, SIADH, hyponatremia, hypocalcemia (additive effects)

  • tramadol
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    tramadol
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + tramadol

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • triamcinolone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    triamcinolone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + triamcinolone

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • triamterene
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    triamterene
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + triamterene

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • triclabendazole
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    triclabendazole
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + triclabendazole

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trifluoperazine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    trifluoperazine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + trifluoperazine

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • trifluridine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    trifluridine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + trifluridine

    monitor ECG: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • trimethoprim
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    trimethoprim
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + trimethoprim

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • trimipramine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    trimipramine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + trimipramine

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • triptorelin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    triptorelin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + triptorelin

    PROSTATE CANCER: monitor ECG, electrolytes; ALL OTHER INDICATIONS: consider monitoring ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects, androgen deprivation may prolong QT)

  • upadacitinib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    upadacitinib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + upadacitinib

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • vamorolone
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    vamorolone
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + vamorolone

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • vancomycin
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    vancomycin
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + vancomycin

    VANCOMYCIN IV: monitor CBC, especially w/ long-term vancomycin; VANCOMYCIN PO use OK: combo may incr. risk of myelosuppression (additive effects)

  • vemurafenib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    vemurafenib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + vemurafenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • venlafaxine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    venlafaxine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + venlafaxine

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • vilanterol inhaled
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    vilanterol inhaled
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + vilanterol inhaled

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

  • vinblastine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    vinblastine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + vinblastine

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • vincristine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    vincristine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + vincristine

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • vinorelbine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    vinorelbine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + vinorelbine

    monitor sodium: combo may incr. risk of SIADH, hyponatremia (additive effects)

  • zidovudine
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    zidovudine
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + zidovudine

    monitor CBC: combo may incr. risk of myelosuppression (additive effects)

  • ziftomenib
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    ziftomenib
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + ziftomenib

    monitor ECG, electrolytes: combo may incr. risk of QT prolongation, cardiac arrhythmias (additive effects)

  • zonisamide
  • Trodelvy (sacituzumab govitecan-hziy) (sacituzumab govitecan)
    +
    zonisamide
    1 interaction

    Monitor/Modify Tx

    sacituzumab govitecan + zonisamide

    monitor potassium: combo may incr. risk of hypokalemia (additive effects)

Adverse Reactions .

Serious Reactions

    com.epocrates.rxweb.beans.StringCollection@6eaac18d
  • neutropenia
  • anemia
  • thrombocytopenia
  • febrile neutropenia
  • sepsis
  • pneumonia
  • UTI
  • diarrhea, severe
  • nausea, severe
  • vomiting, severe
  • neutropenic colitis
  • intestinal perforation
  • intestinal obstruction
  • hypersensitivity reaction
  • anaphylaxis
  • infusion reaction
  • pleural effusion
  • respiratory failure
  • acute kidney injury
  • hypokalemia

Common Reactions

    com.epocrates.rxweb.beans.StringCollection@3e712e26
  • neutropenia
  • diarrhea
  • nausea
  • fatigue
  • alopecia
  • anemia
  • constipation
  • hypersensitivity reaction
  • vomiting
  • appetite decr.
  • abdominal pain
  • cough
  • headache
  • rash
  • dyspnea
  • arthralgia
  • back pain
  • UTI
  • pruritus
  • fever
  • respiratory infection
  • stomatitis
  • dizziness
  • febrile neutropenia
  • insomnia
  • edema
  • dyspepsia
  • hypokalemia
  • neuropathy
  • xeroderma
  • dehydration
  • dysgeusia
  • extremity pain
  • lymphocytes decr.
  • glucose incr.
  • alk phos incr.
  • magnesium decr.
  • calcium decr.
  • ALT or AST incr.
  • phosphate decr.
  • albumin decr.
  • Plt decr.
  • potassium decr.
  • sodium decr.

Safety/Monitoring .

Monitoring Parameters
pregnancy test at baseline; CBC with diff during tx; signs/symptoms of infusion reaction during and for at least 30min after infusion

Pregnancy/Lactation .

Pregnancy

Clinical Summary

weigh risk/benefit during pregnancy; no human or animal data available; possible risk of fetal harm, including teratogenicity and embryo-fetal death, based on drug's mechanism of action

Individuals of Reproductive Potential

obtain pregnancy test before tx start; avoid pregnancy by using effective contraception during tx and x6mo after D/C in patients of childbearing potential and during tx and x3mo after D/C in male patients

Lactation

Clinical Summary

avoid breastfeeding during tx and x1mo after D/C; no human data available to assess risk of infant harm or effects on milk production

Pharmacology .

com.epocrates.rxweb.beans.DrugOtherInfoBean@59cd5b97

Metabolism: for sacituzumab govitecan: catabolism; CYP450: unknown; Info: active drug SN-38 (UGT1A1 substrate)

Excretion: for sacituzumab govitecan: unknown; Half-life: 23.4h (sacituzumab govitecan), 17.6h (SN-38)

Subclass: Immunotherapy, Antibody-Drug Conjugates ; Immunotherapy, TROP-2 Inhibitors ; Mitosis Inhibitors, Topoisomerase I Inhibitors

Mechanism of Action
for sacituzumab govitecan: antibody-drug conjugate binds to trophoblast cell-surface antigen 2 (TROP-2) expressing cells, releases active drug SN-38 intracellularly, which binds to topoisomerase I-DNA complexes, causing DNA damage and apoptosis

Formulary .

No Formulary Selected

Manufacturer/Pricing .

Manufacturer: Gilead Sciences, Inc.

com.epocrates.rxweb.beans.DrugOtherInfoBean@4ebd0b28

DEA/FDA: Rx

Retail Price

Estimated prices only. For current pricing, visit GoodRx.

intravenous powder for injection:

  • 180 mg (1 vial): $2,187.00

Join Now to View Patient Handouts!

Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.

Current Members: Sign In.

Sign Up Now - It's Free >>

Pill Pictures

Join Now to View Pill Pictures!

Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.

Current Members: Sign In.

Sign Up Now - It's Free >>

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information